SELLAS Phase 3 REGAL AML trial hits 80th death, triggering final analysis

SELLAS Life Sciences announced that its pivotal Phase 3 REGAL trial of galinpepimut‑S in acute myeloid leukemia reached the pre‑specified 80th death, which activates the study’s final analysis and database lock. The company said preliminary topline results will be released later this quarter. The milestone coincided with a sharp sell‑off in SELLAS shares, which fell between 15% and 18% on the news.

The final analysis will determine whether the trial meets its overall‑survival endpoint, a key catalyst for the stock. The immediate market reaction was a steep price decline, reflecting heightened short‑term risk for investors.

  • 1The REGAL trial reached the pre‑specified 80th event (deaths), triggering final analysis.
  • 2SELLAS plans to announce preliminary topline primary‑endpoint results this quarter.
  • 3SELLAS shares fell 17% to $10.03 after the announcement.
  • 4SELLAS shares fell 18% after the announcement.
  • 5SELLAS shares fell about 15% to $10.38 on the day of the announcement.
  • 6SELLAS had $138 million in cash as of June 30.
  • The exact percentage decline reported varies: 17%, 18%, and about 15%.

Sources